Bristol Myers previews ESMO. Bristol Myers Squibb stock costs EUR 54.67 before results

Published on 10/21/2026 at 11:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers previews its ESMO 2026 cancer showcase on October 19, 2026. Bristol Myers Squibb stock costs EUR 54.67 before October 29 results.

Pipeline event precedes October results

Bristol Myers Squibb announced its ESMO 2026 showcase on October 19, 2026.
Fiscal year 2025 revenue totaled USD 48.2 billion.
Bristol Myers Squibb stock traded at EUR 54.67 at 11:29 a.m. CEST at Lang & Schwarz on October 21, 2026.
RBC Capital Markets maintained a USD 64.00 target on October 19, 2026.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb (ISIN US1101221083) was trading at EUR 54.67 at Lang & Schwarz on October 21, 2026, at 11:29 a.m. CEST. The company announced an ESMO 2026 showcase on October 19, 2026, putting its cancer pipeline ahead of the next quarterly report.

ESMO showcase sharpens pipeline focus

According to Bristol Myers Squibb, the October 19 investor update highlighted next-generation cancer modalities and leadership across solid tumors at ESMO 2026. The announcement matters because the company is using pipeline progress to support growth as established medicines face competitive and patent pressure.

The company said on October 12, 2026, that the interim analysis of the Phase 3 ACTION-1 trial met its primary endpoint. The official Bristol Myers Squibb said RYZ101 produced a statistically significant and clinically meaningful improvement in progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors.

What does the pipeline mean for revenue?

The financial base remains substantial. Bristol Myers Squibb's investor materials report USD 48.2 billion of total revenue and USD 14.2 billion of operating cash flow for fiscal year 2025, with USD 5.0 billion returned to shareholders. Those figures give the pipeline announcements a measurable commercial frame, but they do not remove execution risk.

For the near-term earnings test, Fidelity reported on October 19, 2026, that RBC Capital Markets maintained a Sector Perform rating and a USD 64.00 price target. RBC also expected Bristol Myers Squibb to beat third-quarter revenue estimates, citing Eliquis, Revlimid, Breyanzi and Reblozyl.

October 29 is the next checkpoint

The investor calendar lists Bristol Myers Squibb's third-quarter 2026 results conference call for October 29, 2026, at 8:00 a.m. ET. The report should connect the ESMO pipeline narrative with revenue trends and the company's ability to replace aging-product sales.

Price stays below the earnings event

At EUR 54.67, the Lang & Schwarz quote places the German trading indication before the October 29 results date. Bristol Myers Squibb is listed on the NYSE under BMY, and its healthcare profile spans oncology, hematology, neuroscience, immunology and cardiovascular medicines.

The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.